AstraZeneca’s baxdrostat shows promise in Phase III hypertension trial
At week 12, the 2mg dose resulted in an absolute SBP decrease of 15.7 mmHg from baseline.
01 September 2025
01 September 2025
At week 12, the 2mg dose resulted in an absolute SBP decrease of 15.7 mmHg from baseline.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.